Effect of MYH10 Variant on Acute Leukemia with Low Platelet Count Prognosis

Abstract

Background: Acute myeloid leukemia (AML) is a blood disorder characterized by abnormal white blood cell count, anemia, or abnormal platelet count. It is associated with molecular genetic changes. While platelet counts vary at first diagnosis，platelets recover after chemotherapy. Objectives:This study aimed to; (1) Investigate whether the platelet count and genotype at first diagnosis are related to chemotherapy and their significance on chemotherapy prognosis; (2) Determine whether newly diagnosed patients with low platelet count have a poor prognosis and if it can be used as a separate prognostic predictor; (3) Determine whether the mutation genotype affects platelet count and its prognosis at first diagnosis. Methods: A retrospective chart review of 301 AML patients was conducted. Univariate, multivariate unconditional Logistic regression and Cox regression analyses were also conducted. Bioinformatics technology was used to extract the GSE12662 data set from the GEO database to analyze differentially expressed genes in AML patients. Besides, biological functions, pathways, proteins, and prognosis were assessed. Conclusion: Increased platelet count in AML patients after chemotherapy was an independent risk factor affecting complete remission. The platelet count also had some guiding significance for evaluating the sensitivity of patients to chemotherapy. MYH10 causes thrombocytopenia in acute myeloid leukemia via RUNX1 gene alteration and influence of prognostic factors. MYH10 variant detection improves the identification of AML molecular characteristics and its prognostic impact on AML, helping in the response analysis to chemotherapeutic agents and further treatment decisions.